Welcome to our dedicated page for Compass Therapeutics news (Ticker: CMPX), a resource for investors and traders seeking the latest updates and insights on Compass Therapeutics stock.
Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. News about CMPX often centers on its antibody pipeline, clinical trial progress, financing activities, and corporate developments, reflecting its focus on angiogenesis, immune modulation, and tumor growth.
Investors and observers following Compass Therapeutics news can expect regular updates on key product candidates such as tovecimig, CTX-8371, CTX-10726, and CTX-471. The company issues press releases on milestones in the COMPANION-002 Phase 2/3 study of tovecimig in advanced biliary tract cancer, monotherapy data in metastatic colorectal cancer, and cohort expansions or new responses in the Phase 1 study of CTX-8371 in indications like non-small cell lung cancer, triple negative breast cancer, and Hodgkin Lymphoma. Preclinical data releases for CTX-10726, including presentations at scientific meetings, also feature prominently.
Compass Therapeutics news coverage additionally includes quarterly financial results, cash and marketable securities updates, and descriptions of anticipated cash runway, as disclosed in earnings press releases and related Form 8-K filings. The company also announces public offerings of common stock and pre-funded warrants, with details on intended use of proceeds for research, clinical development, and preparations for potential commercialization.
Another recurring theme in CMPX news is participation in healthcare and biopharma investor conferences, where Compass presents its pipeline and corporate strategy. Press releases list appearances at events hosted by firms such as J.P. Morgan, Piper Sandler, Evercore, Guggenheim, Stifel, Cantor, and others. Leadership appointments, including additions to the senior management team, are also communicated through Globe Newswire releases.
This news page aggregates these company-issued updates and related coverage, offering a centralized view of clinical, scientific, financial, and corporate developments for Compass Therapeutics and its CMPX stock.
Compass Therapeutics Inc. (Nasdaq: CMPX) announced its presentation of preclinical data on CTX-8371, a bispecific checkpoint inhibitor targeting PD-1 and PD-L1, at the AACR Annual Meeting from April 8-13, 2022. The study, led by Diana Albu, Ph.D., will showcase the antibody's potential to enhance anti-tumor activity in solid tumors by converting PD-1-positive cells to PD-1-negative cells. As part of IND-enabling preclinical development, CTX-8371 shows promise over existing monoclonal antibodies, indicating its unique mechanism could mitigate immune suppression effectively.
Compass Therapeutics reported a strong financial position with $144.5 million in cash as of 2021, bolstered by a $136 million public offering. The company is advancing its clinical pipeline, particularly the CTX-009 study for advanced biliary tract cancers, which met response criteria for progression to Phase 2. Additionally, CTX-471 showed encouraging results in patients with solid tumors. However, the company faced a net loss of $82.2 million for 2021, with R&D expenses rising significantly to $20.3 million, marking a 36% increase from 2020. The company expects to sustain operations into late 2024.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced the FDA has cleared its IND application for CTX-009, enabling a global Phase 2 trial for Biliary Tract Cancers (BTC) in the U.S. and South Korea. CTX-009 is a bispecific antibody targeting DLL4 and VEGF-A, showing clinical benefit in heavily pre-treated patients. The ongoing Phase 2 study in South Korea has completed Stage 1, achieving a 29% overall response rate and a 100% clinical benefit rate. Expansion to U.S. sites is planned for Q2 2022, presenting potential growth opportunities for the company.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced that CEO Thomas Schuetz will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, from 8:15 to 8:55 a.m. ET. The presentation will be virtual, with details to be updated on the company's investor webpage. Compass Therapeutics focuses on antibody-based therapeutics for cancer treatment, exploring the interplay between angiogenesis, the immune system, and tumor growth. Established in 2014 and based in Boston, Massachusetts, the company aims to advance its innovative pipeline through clinical development.
Compass Therapeutics, Inc. (Nasdaq: CMPX) announced that CEO Thomas J. Schuetz, MD, PhD, will present at the Piper Sandler 33rd Annual Healthcare Conference held virtually from November 29 to December 2, 2021. The presentation will be available on-demand from November 22 to December 2, 2021. Compass Therapeutics focuses on developing proprietary antibody-based therapeutics targeting cancer through modulating immune responses and angiogenesis. Founded in 2014 and based in Boston, Massachusetts, the company aims to advance its clinical pipeline.
Compass Therapeutics reported progress in its clinical studies and financial results for Q3 2021. The company advanced CTX-009 to the second stage of a Phase 2a study, with a 29% overall response rate observed in 17 patients. CTX-471 demonstrated two partial responses in melanoma patients. The recent public offering raised $125 million, extending its cash runway into Q4 2024. R&D expenses decreased to $3.2 million, and general and administrative expenses dropped to $2.7 million. The net loss was $6 million, or $0.10 per share, an improvement from the previous year.
Compass Therapeutics, Inc. announced a public offering of 35,715,000 shares at $3.50 each, expected to raise approximately $125 million. The offering will close on November 4, 2021, and includes an option for underwriters to purchase an additional 5,357,250 shares. This follows the company's listing on the Nasdaq Capital Market under the symbol CMPX, effective November 2, 2021. Proceeds will fund ongoing clinical trials and operations. SVB Leerink is the book-running manager for the offering.
Compass Therapeutics, Inc. announces an underwritten public offering of shares of common stock, intending to secure its listing on the Nasdaq Capital Market under the symbol CMPX. The company expects to grant underwriters a 30-day option to purchase an additional 15% of the shares. Proceeds from the offering will fund clinical trials for ongoing operations and general corporate purposes. Offering details are based on a previously effective shelf registration statement. SVB Leerink is the book-running manager.
Compass Therapeutics (CMPX) announced progress on the Phase 2a study of CTX-009 for biliary tract cancers, initiated in Q1 2021 by Handok Pharmaceuticals. The study has met its criteria to advance, revealing a preliminary overall response rate of 29% with five partial responses from 17 patients. Additionally, 100% experienced stable disease or better. Compass plans to submit an Investigational New Drug (IND) application to the FDA this quarter, with a Phase 2 study anticipated in Q2 2022, aiming to enhance treatment options for cholangiocarcinoma.
Compass Therapeutics (OTC:CMPX) presented promising clinical data for CTX-009, a bispecific antibody targeting DLL4 and VEGF-A, at the AACR-NCI-EORTC conference. In a Phase 1 trial involving heavily pre-treated patients with colorectal and gastric cancers, CTX-009 showed an overall response rate (ORR) of 19% at recommended doses, with a disease control rate (DCR) of 69%. The drug was well tolerated, with no dose-limiting toxicities reported. Ongoing studies include a Phase 1b combination trial and a Phase 2 trial, enhancing its potential as a treatment for resistant solid tumors.
FAQ
What is the current stock price of Compass Therapeutics (CMPX)?
What is the market cap of Compass Therapeutics (CMPX)?
